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Abstract Dihydropyrimidine dehydrogenase (DPD) defi-
ciency is an autosomal recessive disorder of pyrimidine
metabolism that impairs the first step of uracil und thymine
degradation. The spectrum of clinical presentations in
subjects with the full biochemical phenotype of DPD defi-
ciency ranges from asymptomatic individuals to severely
affected patients suffering from seizures, microcephaly,
muscular hypotonia , developmental delay and
eye abnormalities.
We report on a boy with intellectual disability, signifi-
cant impairment of speech development, highly active epi-
leptiform discharges on EEG, microcephaly and impaired
gross-motor development. This clinical presentation trig-
gered metabolic workup that demonstrated the biochemical
phenotype of DPD deficiency, which was confirmed by
enzymatic and molecular genetic studies. The patient
proved to be homozygous for a novel c.2059-22T>G
mutation which resulted in an in-frame insertion of 21 base
pairs (c.2059-21_c.2059-1) of intron 16 of DPYD.
Family investigation showed that the asymptomatic father
was also homozygous for the same mutation and enzymatic
and biochemical findings were similar to his severely
affected son. When the child deteriorated clinically, exome
sequencing was initiated under the hypothesis that DPD
deficiency did not explain the phenotype completely. A
deletion of the maternal allele on chromosome 15q11.2-13-
1 was identified allowing the diagnosis of Angelman syn-
drome (AS). This diagnosis explains the patient’s clinical
presentation sufficiently; the influence of DPD deficiency
on the phenotype, however, remains uncertain.
Introduction
Dihydropyrimidine dehydrogenase (DPD) deficiency is a
rare autosomal recessive disorder that was first described in
the 1980s (van Gennip et al. 1981; Bakkeren et al. 1984).
Dihydropyrimidine dehydrogenase catalyses the first and
rate-limiting step of uracil and thymine degradation.
Biochemical hallmark of enzyme deficiency is the excretion
of uracil and thymine in urine, which is easily detected by
basic metabolic work-up. DPD deficiency has been asso-
ciated with severe, early-onset neurological symptoms
such as seizures, microcephaly, muscular hypotonia, global
developmental delay and eye abnormalities (e.g. micro-
cornea, nystagmus and hypoplastic macula) (Yau et al.
2004; Van Kuilenburg et al. 1999; Braakhekke et al. 1987;
Bakker et al. 1994). EEG-abnormalities encompass various
types of epileptic discharges (Braakhekke et al. 1987).
However, the biochemical phenotype has also been
observed in asymptomatic individuals (Van Kuilenburg
et al. 1999; Braakhekke et al. 1987; Van Gennip et al.
1994).
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Brain magnetic resonance imaging (MRI) in individuals
with DPD deficiency showed normal brain morphology in
some individuals; non-specific findings (e.g. cerebral
atrophy or white matter T2-hyperintensity) have also been
described (Enns et al. 2004).
Angelman syndrome (AS) has initially been described in
1965 in three unrelated children with “puppet-like” gait,
microcephaly, dysmorphic facial features, paroxysms of
laughter and severe mental disability (Angelman 1965). AS
is caused by loss of function of the ubiquitin protein ligase
E3A (UBE3A) gene on the maternally derived chromosome
15. In 75% of cases, an interstitial deletion of the maternal
part of the chromosome is causative. Genomic imprinting
defects, paternal uniparenteral disomy of chromosome 15
and intragenic mutations or deletions of UBE3A gene have
also been reported as causes for AS (Buiting et al. 2016).
As in DPD deficiency, the MRI-features in AS are rather
unspecific. Thinning of the corpus callosum, enlargement
of the lateral ventricles and cerebral atrophy with frontal
and temporal predominance have been described. The EEG
changes in AS encompass three quite distinctive main
patterns: rhythmic high amplitude 2–3 Hz activity predomi-
nantly over the frontal regions; rhythmic high amplitude
4–6 Hz activity or 4–5 Hz spike waves over the parieto-
occipital regions after eye closure. These patterns may
appear isolated or in various combinations and often evolve
over time in affected individuals (Buiting et al. 2016; Boyd
et al. 1988). The major characteristic in AS is, however,
neither the MRI nor the EEG but development and
behaviour, which can be characterised as severe intellectual
disability, absence of speech, paroxysmal periods of
laughter, sleeping disturbances including reversal of the
day-night rhythm, and extreme hyperactivity which can
result in uncontrolled movements due to ataxia.
Case Report
Our patient was the first male child born to healthy,
consanguineous (second cousins) Turkish parents (Fig. 1).
He was born at term by secondary caesarean section;
auxologic parameters were normal and neonatal adaptation
uneventful.
At 4 weeks, the child had been hospitalised with an
acute infection, feeding difficulties and failure to thrive, and
metabolic workup was initiated. Determination of uracil
and thymine concentrations in urine using reversed-phase
HPLC hyphenated with electrospray tandem mass spec-
trometry (van Lenthe et al. 2000) demonstrated excessive
excretion of uracil and thymine, indicating DPD deficiency
(Table 1).
For enzymatic testing, peripheral blood mononuclear
(PBM) cells were isolated and the activity of DPD was
determined in a reaction mixture containing 35 mM
potassium phosphate (pH 7.4), 2.5 mM MgCl2, 1 mM
dithiothreitol, 250 mM NADPH and 25 mM [4-14C]-
thymine. Separation of radiolabeled thymine from radio-
labeled dihydrothymine was performed by reversed-phase
HPLC with online detection of the radioactivity, as
described before (van Kuilenburg et al. 2000b). The patient
showed an almost complete deficiency of DPD activity
(Table 1).
DNAwas isolated from blood using standard techniques.
PCR amplification of all 23 coding exons and flanking
intronic regions of DPYD was carried out using intronic
primer sets, essentially as described before (van Kuilenburg
et al. 2000a). Sequence analysis of genomic fragments
Fig. 1 Family tree over four generations
Table 1 DPD activity and pyrimidine bases in affected family
members
Tissue
DPD
activity
(nmol/
mg/h)
Uracil
(mmol/
mmol
creatinine)
Thymine
(mmol/mmol
creatinine)
Son PBM cells 0.2
Fibroblasts < 0.02
Urine 562 288
Father PBM cells 0.1
Fibroblasts <0.02
Urine 141 42
Controls PBM cellsa 9.9  2.8
Fibroblastsb 1.1  1.2
Urinec 11.8  9.1 0.5  0.6
a Data from van Kuilenburg et al. (2002)
b Data from van Kuilenburg et al. (2000b)
c Data from van Kuilenburg et al. (2004b)
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amplified by PCR was carried out on an Applied
Biosystems model 3,730 automated DNA sequencer using
the dye-terminator method (Applied Biosystems, Nieuwer-
kerk a/d IJssel, The Netherlands). The DPYD sequence of
DPD deficient patients were compared to those observed in
controls and the reference sequence of DPYD (Ref Seq
NM_000110.3; Ensembl ENST00000370192). Total RNA
was isolated from cultured fibroblasts using Trizol extrac-
tion (Invitrogen, Carlsbad, CA, USA). Subsequently, cDNA
was prepared using a first strand cDNA synthesis kit for
RT-PCR (Roche, Mannheim, Germany). PCR amplification
of a part of the cDNA sequence containing exon 13–19 was
performed using the forward primer (50-TTGATCTGGTG-
GACATTAGTG-30) and reverse primer (50-GAAACT-
GAAGACCACTTTCAG-3 0), corresponding to the
nucleotides c.1583_1603 (exon 13) and c.2396_2416 (exon
19), respectively. Genetic testing in the patient revealed a
novel homozygous mutation in intron 16 (c.2059-22T>G)
of the DPYD gene, leading to homozygosity for an in-frame
insertion of 21 bp (2058_2059ins21) corresponding to the
nucleotides c.2059-21_c.2059-1 of intron 16 of DPYD
(Fig. 2). Consequently, additional seven amino acids (p.
Gln686_Asp687ins7) are included into the mature DPD
protein, which most likely has a deleterious effect on
protein function.
Work-up of the family showed that the mother was a
heterozygous carrier. Surprisingly the completely asymp-
tomatic father was also homozygous for the c.2059-22T>G
mutation and had comparable enzymatic and biochemical
findings as observed in his affected son (Table 1). The
father had never encountered any neurological problems,
had completed junior high school and was presently
employed as a semiskilled worker.
From the age of 12 months, the paediatrician noticed
developmental impairment and generalised muscular hypo-
tonia. At 19 months, the child presented with failure to
thrive and microcephaly (body weight and head circum-
ference <3rd centile). He was able to sit unsupported but
had not yet started to walk. His movements were poorly
coordinated. Speech development, play behaviour and
social skills corresponded to a developmental age of
approximately 10 months. MRI of the brain revealed
unspecific symmetric T2-hyperintense lesions in the
occipital white matter region. EEG registered 4–5 Hz
Fig. 2 Alternative DPD pre-MRA splicing due to the c.2059-22T>G
mutation in DPYD. The cDNA sequence of part of exon 16 and 17 is
shown for a control (panel a), the father (panel b) and the affected son
(panel c). The in-frame insertion of 21 base pairs (c.2059-21_c.2059-
1) of intron 16 is underlined in blue. Panel (d) shows a schematic
representation of the region of intron 16 upstream of exon 17 and the
effect of the c.2059-22T>G mutation on splicing of the DPD pre-
mRNA. The intronic sequence inserted into the DPD mRNA is
indicated in capital letters. The cryptic splice acceptor site is
underlined
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parieto-occipital spike waves; the parents had never
perceived seizures. Treatment with valproic acid improved
the patient’s overall condition and development and
alleviated the EEG. He learned to ambulate one hand-
guided and made remarkable progress in speech compre-
hension, play behaviour and social skills. Until age
3.5 years, he has not developed active speech but learned
to use basal augmentative communication; his movements
remain uncoordinated.
Against the background of the genetic, enzymatic and
biochemical findings in the asymptomatic father and the
severe, but at this time rather nonspecific phenotype in the
child we decided to search for further causes for develop-
mental delay and initiated exome sequencing. A deletion of
the maternal allele of chromosome 15q11.2-13-1 causative
for AS was identified (Fig. 3) (Buiting et al. 2016).
During the further course, the clinical phenotype of AS
evolved more and more. At 3 years, the parents reported
paroxysm of laughter, he showed hyperactivity and ataxia,
he was microcephalic and the characteristic EEG pattern
with rhythmic frontal high amplitude 2–3 Hz activity and
rhythmic high amplitude 4–6 Hz activity in addition to the
previously described 4–5 Hz spike waves over the parieto-
occipital regions was recorded.
Discussion
In the patient presented here, overall developmental delay
triggered basic metabolic work-up, which resulted in the
identification of DPD deficiency. Enzymatic and molecular
genetic studies were consistent with the biochemical pheno-
type. However, as the healthy father had the identical gene-
tic and biochemical phenotype and further studies in the
index patient showed signs unusual for DPD deficiency,
additional studies were performed that finally demonstrated
AS. Characteristic signs of AS such as microcephaly,
delayed development and characteristic EEG features were
encountered in the patient (Buiting et al. 2016).
Until now, firm genotype–phenotype correlations in
DPD deficiency have not been established and -like in the
reported family- asymptomatic individuals have repeatedly
been identified (Van Kuilenburg et al. 1999; Braakhekke
et al. 1987; Van Gennip et al. 1994).
This broad phenotypic spectrum indicates a variable
penetrance of DPD deficiency. Additional factors such as
other metabolites in pyrimidine catabolism, and oxidative
stress or febrile infections as triggers may be involved in
the development of the clinical phenotype and may even
lead to sudden, eventually devastating neurologic disease in
Fig. 3 Methylation specific MLPA of the PWS/AS region on chromosome 15q11–q13. (a) Absence of methylation at the differential methylated
sites (DMRs) at the SNRPN locus. (b) Heterozygous deletion between genes TUBGCP5 and APBA2
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formerly asymptomatic individuals (Fiumara et al. 2003;
Van Kuilenburg et al. 2006). The mechanism behind this,
however, has not been elucidated yet. Furthermore, it has
been suggested that mutations in other, yet unknown genes
and epigenetic influences may be linked to mutations in
DPYD and thus involved in the development of the clinical
phenotype (Van Kuilenburg et al. 1999).
Epilepsy is a feature often encountered in DPD defi-
ciency. Therefore, it is an interesting observation that in
DPD patients, plasma beta-aminoisobutyric acid (ß-AIB), a
downstream metabolite in thymine catabolism, is signifi-
cantly decreased (van Kuilenburg et al. 2004a). The
molecular structure of ß-AIB is very similar to gamma-
aminobutyric acid and glycine, two of the most important
inhibitors of neuronal synaptic transmission. It has therefore
been hypothesised that ß-AIB may also be involved in
inhibitory synaptic regulation. Following this line of
thought, low ß-AIB may contribute to the imbalance
between excitatory and inhibitory agents and thus play a
role in seizure aetiology in DPD. Since plasma concen-
trations of ß-AIB levels are very low in DPD patients this
parameter may unfortunately not be useful to differentiate
between mild and severely affected individuals (Van
Kuilenburg et al. 2004a).
We conclude that more investigations are necessary to
elucidate possible pathogenic mechanisms behind the
variable phenotype of DPD. We recommend thorough
diagnostic workup of patients with the DPD biochemical
phenotype beyond DPD in case the clinical course is
suggestive of another disease or not consistent with clinical
observations in DPD deficiency.
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